Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.
Prostate Cancer
DRUG: kanglaite gelcap|DRUG: Kanglaite gelcap
prostate specific antigen doubling time (PSADT), PSADT is defined as the natural log of 2 (0.693)divided by the slope (beta- rate of change) of the relationship between the log of PSA and the time of PSA measurement using linear regression model, over 12 months on study drug
PSA objective response, a 50% or more decline in PSA level compared to baseline, over 12 months on study drug|KLTc intake compliance, actual number of capsules taken divided by the expected number of capsules taken multiplied by 100 to get a percentage of compliance, each month, up to 12 months on study drug
This research is being done to evaluate the safety and efficacy of the investigational Kanglaite gelcap (KLTc) on PSA in men with prostate cancer when given for twelve months.